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1 
 
ABSTRACT 
 
Mitochondrial dysfunc on has been implicated in the ae ology of monogenic Parkinson’s disease (PD).             
Yet the role that mitochondrial processes play in the most common form of the disease; sporadic PD, is                  
yet to be fully established. Here we comprehensively assessed the role of mitochondrial func on              
associated genes in sporadic PD by leveraging improvements in the scale and analysis of PD GWAS data                 
with recent advances in our understanding of the gene cs of mitochondrial disease.  First, we iden ﬁed               
that a propor on of the “missing heritability” of PD can be explained by common varia on within genes                 
implicated mitochondrial func on (secondary gene list). Next we calculated a mitochondrial-speciﬁc           
polygenic risk score (PRS) and showed that cumula ve small eﬀect variants within both our primary and                
secondary gene lists are signiﬁcantly associated with increased PD risk. Most signiﬁcantly we further              
report that the PRS of the secondary mitochondrial gene list was signiﬁcantly associated with later age at                 
onset. Finally, to iden fy possible func onal genomic associa ons we implemented Mendelian           
randomisa on, which showed that 14 of these mitochondrial func on associated genes showed            
func onal consequence associated with PD risk. Further analysis suggested that the 14 iden ﬁed genes              
are not only involved in mitophagy but implicate new mitochondrial processes. Our data suggests that               
therapeu cs targe ng mitochondrial bioenerge cs and proteostasis pathways dis nct from mitophagy          
could be beneﬁcial to trea ng the early stage of  PD.  
 
  
2 
INTRODUCTION  
  
Parkinson’s disease (PD) is a progressive neurodegenera ve movement disorder characterized 
pathologically by the death of dopaminergic neurons in the substan a nigra (SN) and aggrega on of 
α-synuclein protein (encoded by  SNCA ), within intraneuronal inclusions called Lewy bodies. The majority 
of PD cases are apparently sporadic in nature (~95%). Aging is a major risk factor for disease and due to 
popula on ageing the prevalence of PD is predicted to increase rapidly, making the iden ﬁca on of 
therapeu c targets a high priority 1–3  . 
  
Although there have been great advances in understanding both the gene c architecture and cellular 
processes involved in PD, the exact molecular mechanisms that underlie PD remain unknown  1 . However, 
it is suggested that PD has a complex e ology, involving several molecular pathways, and understanding 
these speciﬁc pathways will be key to establishing mechanis c targets for therapeu c interven on. 
While several key pathways are currently being inves gated, including  autophagy, endocytosis, immune 
response and lysosomal func on ,  4–7  mitochondrial func on was the ﬁrst biological process to be 
associated with PD  8,9 . 
  
An interest in mitochondrial func on and PD began with the observa on that exposure to the drug 
1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) can cause rapid parkinsonism and neuronal loss in 
the SN in humans, and that this is mediated through inhibi on of complex I of the mitochondrial 
electron transport chain  7,10 , 11 . Subsequent work suggested that individuals with sporadic PD have 
reduced complex I ac vity not only in the SN, but in other brain regions and peripheral  ssues  12 . Gene c 
studies focusing on monogenic forms of PD provided further support for the involvement of 
mitochondrial dysfunc on in the disease. Pathogenic muta ons that lead to autosomal recessive forms 
of PD have been reported in  PINK1 ,  PARK2, PARK7 ,  CHCHD2 and  VPS13C and the proteins they encode 
are all now known to be involved in the mitochondrial quality control system and in par cular mitophagy 
13–16 .  
 
Therefore in this paper, we aim to comprehensively  assess the role of mitochondrial func on in sporadic 
PD by leveraging improvements in the scale and analysis of PD genome wide associa on study (GWAS) 
data with recent advances in our understanding of the gene cs of mitochondrial disease.  The availability 
of large scale genome wide associa on data in PD cases and the rapid iden ﬁca on of gene c lesions 
that underlie mitochondrial disease provide an opportunity to systema cally assess the role of gene c 
variability in mitochondrial linked genes in the context of risk for PD 17 .  In this study we combine these 
new resources with current sta s cal tools, such as polygenic risk scoring and Mendelian randomisa on, 
to explore the role of mitochondrial func on in both PD risk and age at onset of disease to obtain novel 
insights. 
 
 
 
 
 
 
3 
RESULTS  
 
Common variation within mitochondria function genes contributes to the heritable component of PD 
 
The general workﬂow for the gene c analysis used in this study is shown in  Figure 1.  First, to study the 
importance of mitochondrial func on in sporadic PD, we inves gated the heritability of PD speciﬁcally 
within genomic regions that contained genes annotated as important in mitochondrial func on. The 
construc on of this annota on was driven by the principle that genomic regions, which are known to be 
the sites of muta ons in individuals with rare mitochondrial diseases or are candidate regions for such 
muta ons provide the best evidence for involvement in mitochondrial func on.  
 
GCTA is a sta s cal method that es mates phenotypic variance of complex traits explained by 
genome-wide SNPs, including those not associated with the trait in a GWAS.  Using GCTA, heritability 
es mates were ﬁrst calculated for the four largest IPDGC GWAS datasets  and including all variants 
( WTCCC PD GWAS (PMID:21044948), Spanish Parkinson's (IPDGC) part2, NIA PD GWAS 
(PMID:19915575), Dutch GWAS (PMID:21248740 ). Due to the low number of included cases, the 
heritability es mates in the other IPDGC datasets were deemed less reliable. Consistent with previous 
heritability es mates from both Keller and colleagues (2012; 24%) and Chang and colleagues (2017; 
21%), our random eﬀects meta analysis for the four datasets iden ﬁed 23% (95% CI 12-34, p= 2.72E-05) 
phenotypic variance associated with all PD samples ( Table 1 & 2 ). There was a high degree of consistency 
across the cohorts. 
  
A er establishing the consistency of our heritability es mates we next calculated heritability using only 
variants located within genic regions speciﬁed as being of primary (n=176) or secondary (n=1463) 
importance in mitochondrial func on.  Ini ally, to assess the full contribu on of the mitochondria 
pathway we ran the analysis including and excluding the PD risk genes.   6  However as shown in 
Supplementary Figure 1  there was li le diﬀerence overall in the heritability es mates. Therefore, to 
only to catalog mitochondria speciﬁc gene c risk outside of known loci we focused on the analysis 
excluding these genes.  The heritability es mate using a random-eﬀects meta-analysis for the primary 
gene list  excluding the PD genes  was es mated to be a modest 0.26% (95% CI -0.11-0.66, p=0.166). 
However, the heritability es mate using a random-eﬀects meta-analysis for the secondary list, namely 
genes implicated in mitochondrial func on or morphology as well as disease, was es mated to be 1.67% 
(95% CI -0.07-0.32, p=0.041).  
 
Mitochondria function specific polygenic risk score is significantly associated with disease status  
 
Next we calculated PRS to capture the addic ve eﬀect of all common variants within genes implicated in 
mitochondria func on on PD risk. PRS is a par cularly powerful approach in this context because it is 
able to eﬃciently incorporate informa on from all hits including sub-signiﬁcant hits, which may 
nonetheless be e ologically relevant.  Again, ini ally we ran the analysis including and excluding the PD 
risk genes and the comparison can be seen in  Supplementary Figure 2.  But to only report novel 
associa ons we focused on the lists excluding the PD risk genes.  
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Using this approach the primary and secondary mitochondrial genomic annota ons were found to be 
signiﬁcantly associated with PD disease status. Remarkably, the primary gene list consis ng of only 176 
genes implicated in Mendelian mitochondrial disorders, was associated with PD with an odds ra o of 
1.12 per standard devia on increase in the PRS from the popula on mean (random-eﬀects p-value = 
6.00E-04, beta = 0.11, SE = 0.03).  The secondary gene list, which also included genes implicated in 
mitochondria func on or morphology, was associated with PD with a higher odds ra o of 1.28 per 
standard devia on increase in the PRS from the popula on mean (random-eﬀects p-value =1.9E-22, beta 
= 0.25, SE = 0.03)( Figure 2 ). Together, these analyses not only provide further support for importance of 
mitochondrial processes in PD, but poten ally provide a tool for iden fying PD pa ents most likely to 
beneﬁt from treatments speciﬁcally targe ng mitochondrial func on.  
 
Mitochondria function-specific polygenic risk score is significantly associated with later age at onset 
 
Although mul ple lines of evidence point to the importance of mitochondrial dysfunc on as a primary 
cause of PD, impaired mitochondrial dynamics appears to be common to a wide range of 
neurodegenera ve diseases including Hun ngton’s disease 18,19 , amyotrophic lateral sclerosis 20,21  and 
Alzheimer’s disease 22–25 . The la er suggests that even when impaired mitochondrial func on is not the 
primary event in disease pathogenesis, it is a common outcome and could contribute to disease 
progression. We sought to test this hypothesis by inves ga ng the importance of common varia on 
within our mitochondrial gene lists in determining the age at onset of PD (AAO). Given the signiﬁcant lag 
period between PD pathophysiology and symptoms, AAO was used as an indirect measure of disease 
progression. This analysis was performed using PRS since it has been consistently found to be the main 
gene c predictor of AAO  6,26 27,28  with higher gene c risk scores being signiﬁcantly associated with an 
overall trend for earlier AAO of disease.  While the primary mitochondrial gene list was not signiﬁcantly 
associated with AAO of disease, the secondary gene list was correlated with AAO. Contrary to 
expecta on, the cumula ve burden of common variants within the 1463 genes comprising the PRS for 
PD risk, were posi vely correlated with AAO of PD. A er meta-analysing, we found that each 1SD 
increase in PRS, led to a 0.55 year increase in the AAO of disease (summary eﬀect =  0.211, 95%CI 
( 0.141-0.970 ),| 2  = 68.49 %, p-value= 9.00E-03 ,  Figure 3 ).  As the forest plots demonstrate, although there 
was a rela vely high heterogeneity across studies, the direc onality and magnitude of eﬀect on AAO 
were in concordance with the meta-analysis with the excep on of the Oslo cohort. This ﬁnding  could 
suggest that ﬁrstly, disease causa on and progression are gene cally separable processes in PD and that 
secondly the role of mitochondrial dysfunc on in PD is likely to be highly complex with mul ple dis nct 
mitochondrial processes likely to be involved at diﬀerent disease stages. 
 
MR suggests potential causal association of fourteen novel mitochondria function genes with PD risk  
 
Given the robust evidence for the involvement of mitochondrial func on in sporadic PD, next we used 
two sample MR analysis to iden fy speciﬁc genes likely to be important in PD risk.  MR uses  gene c 
variants to iden fy if an observed associa on between a risk factor and an outcome is consistent with 
causal eﬀect   29 . This method has been implemented  in several recent gene c studies to iden fy 
associa on between  expression quan ta ve trait loci  ( QTL), to more accurately nominate candidate 
genes within risk loci. Therefore for this study, in the aim of iden fying whether changes in expression of 
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mitochondria func on genes are poten ally causally related to PD risk, two-sample MR was 
implemented.  
 
 
Since we wanted to iden fy novel associa ons, we excluded genes already linked to PD through the 
most recent GWAS meta-analysis 6 .  This resulted in the exclusion of 31 genes linked to mitochondrial 
func on and in linkage disequilibrium with the top PD risk variants. Analysis of the remaining 1432 genes 
(generated by combining the primary and secondary gene lists) resulted in the iden ﬁca on of fourteen 
novel genes linked to mitochondrial func on and causally associated with PD risk ( Table 3 ). Of the 
fourteen genes, the expression of 5 genes ( CLN8, MPI, LGALS3, CAPRIN2  and  MUC1)  was posi vely 
associated with PD risk in blood. Similarly, in brain PD risk was associated with increased expression of 
ATG14, E2F1 , and  EP300  in brain  .  However, nega ve associa ons in brain and blood expression were 
observed for  MRPS34  and  PTPN1 and LMBRD1  respec vely. Finally, elevated methyla on of  FASN  in the 
brain was found to be posi vely associated with PD risk but elevated methyla on of  CRY2  was found to 
be inversely correlated.  
 
Six of the fourteen novel PD risk genes we iden ﬁed ( CLN8 ,  EP300 ,  LMBRD1 ,  MPI ,  MRPS34 and  MUC1 ) 
are already associated with a monogenic disorder ( Table 3 ). We noted that neurological abnormali es 
were a feature of the condi on in ﬁve of the six cases with Combined Oxida ve Phosphoryla on 
Deﬁciency 32 due to biallelic muta ons in  MRPS34 being perhaps of par cular interest. In common with 
PD, this condi on is associated with abnormali es of movement, including dystonia and choreoathetoid 
movements. Muta ons causing this condi on result in decreased levels of  MRPS34 protein causing 
destabilisa on of the small mitochondrial ribosome subunit and sugges ng the involvement of 
mitochondrial processes dis nct from mitophagy and mitochondrial homeostasis in PD. In this context, it 
is noteworthy that  MRPL43,  another nuclear gene encoding for a component of the large mitochondrial 
ribosome subunit is also highlighted by the MR analysis. Thus, this analysis not only enabled us to 
iden fy speciﬁc genes of interest, but also pointed to the role of mul ple mitochondrial processes in PD 
dis nct from mitophagy. 
 
  
Exploring the expression of the novel mitochondria risk genes provides additional support for their 
role in PD 
 
We leveraged publicly available cell-speciﬁc and  ssue-speciﬁc gene expression data to inves gate the 
14 mitochondria genes implicated in PD through MR. First, we used enrichment-weighted cell-type 
enrichment (EWCE) to determine whether the expression of mitochondrial PD-associated genes (as 
iden ﬁed through MR and described above, n= 14) was enriched within a speciﬁc cell-type class or their 
subtypes. No signiﬁcant enrichment of these genes was found in any of the tested neuronal and glial 
cell-type classes (  Supplementary Table 6, Supplementary Figure  3 ). Next, we used co-expression 
network analysis to iden fy possible func onal interac ons between the 14 novel mitochondrial genes 
iden ﬁed through MR and genes implicated in monogenic forms of PD. We found that ﬁve of the 14 
genes assessed,  CLN8 ,  FASN ,  MPI ,  MRPL43 and  MRPS3 , were highly co-expressed with at least one gene 
already implicated in monogenic PD in mul ple brain regions (>3 brain regions,  Supplementary Table 7 ). 
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Interes ngly, in the case of CLN8,  MRPL43 and  MRPS4 , our novel genes were co-expressed with a 
monogenic PD gene already implicated in mitochondrial func on such as  PARK7 . Furthermore, with the 
excep on of  CLN8 , ( FASN ,  MPI ,  MRPL43 and  MRPS3 ), the novel mitochondrial gene was assigned to a 
co-expression module enriched for neuronal markers ( Table 4, Supplementary Table 8 ). 
 
 
 
 
 
 
 
 
 
DISCUSSION  
 
We ﬁrst demonstrate that a propor on of the “missing heritability” of sporadic PD can be explained by                 
addi ve commo n gene c var ia on within genes implicated in mitochondrial func on, even a er            
exclusion of genes previously linked to PD through linkage disequilibrium with the top risk variants               
4–6,30–34 . We iden fy that the overall heritability of PD is approximately 23% (Table 2) and that when                 
heritability is calculated for the secondary gene list regions alone we can a ribute around 7% of the                 
overall heritability (23%) to common varia on within the mitochondria func on associated genes.            
Although this ini ally looks like a low es mate, to put this into context, when heritability was calculated                 
in the most recent meta-analysis using the top PD risk hits, this es mate explained only 26-36% of the                  
overall heritability  6 . In addi on, using PRS, which eﬃciently incorporates informa on from            
sub-signiﬁcant hits, we showed that cumula ve small eﬀect variants within only 196 genes linked to               
monogenic mitochondrial disease signiﬁcantly associated with increased PD risk (with odds ra os of 1.12              
per standard devia on increase in PRS from the popula on mean). These ﬁndings are important for two                
main reasons. Firstly, given that risk proﬁling performed in the recent PD meta-analysis did not iden fy a                 
signiﬁcant associa on with mitochondrial func on  4–6,30–34  17 . Secondly, since the primary gene list             
consisted solely of the 196 genes mutated in monogenic mitochondrial disorders, this analysis highlights              
the increasingly close rela onship between Mendelian and complex disease 7 .  
 
In order to maximise the u lity of this study, we used MR which iden ﬁed 14 speciﬁc mitochondrial                 
genes of interest with puta ve func onal consequences in PD risk. We found that although a number of                 
the genes we iden ﬁed are clearly linked to known PD-related pathways, such as lysosomal dysfunc on               
in the case of  CLN8 and  LMBRD1 or autophagy in the case of  ATG14 , others appeared to point towards                   
new processes. In par cular, this analysis highlighted the mitochondrial ribosome through the            
iden ﬁca on of the genes,  MRPL43 and  MRPS34 , encoding components of the large and small              
mitochondrial ribosome subunits respec vely. Interes ngly, biallelic muta ons in  MRPS34 are known to            
cause a form of Leigh syndrome, characterised by neurodegenera on in infancy with dystonia and              
choreoathetoid movements due to basal ganglia dysfunc on. Furthermore, we note that a recent study              
that u lized whole exome sequencing (WES) data from two PD cohorts to inves gate  35,36 rare varia on in                
nuclear genes associated with dis nct mitochondrial processes, not only provided support for the             
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involvement of mitochondrial func on in sporadic PD, but also iden ﬁed the gene,  MRPL43, which              
encodes a component of the large mitochondrial ribosomal subunit 37 .  Interes ngly,  MRPL43 and            
MRPS34 were amongst ﬁve genes which were also highly co-expressed in human brain with genes               
already known to cause monogenic forms of PD. Whereas  MRPL43 and  MRPS34 were highly              
co-expressed with  PARK7 in modules enriched for neuronal markers,  FASN and  MPI were co-expressed              
with  ATP13A2, and  CLN8 was located in modules containing  FBXO7 and enriched for oligodendrocyte              
markers. While this form of analysis does not provide informa on at the single cell level, it points to the                   
possibility of pathway interac ons between these gene sets. However, most importantly it implicates             
en rely dis nct mitochondrial processes in PD risk.  
 
Finally and perhaps most remarkably using our mitochondrial gene lists we observe clear diﬀerences              
between disease causa on and AAO in PD. Although PRS of the primary mitochondrial gene list was not                 
signiﬁcantly associated with AAO, the PRS of the secondary mitochondrial gene list was posi vely              
correlated (p value =3.6E-05), indica ng associa on with later age at onset. However, given these              
ﬁndings it seems plausible that some mitochondrial processes may contribute to PD risk. Thus, this               
analysis is consistent with the ﬁndings of the most recent and largest AAO PD GWAS, which reported                 
that not all the well-established risk loci are associated with AAO and suggested a diﬀerent mechanisms                
for PD causa on and AAO  38 .  This has also been shown in previous studies that have shown no                  
associa on of risk loci with AAO in sporadic PD 35,39 .  
 
Although in this study we have comprehensively analyzed the largest PD datasets currently available with               
very speciﬁc and inclusive mitochondrial func on gene lists, there are a number of limita ons to our                
analyses. Firstly, there was a rela ve amount of heterogeneity in  AAO within the AAO GWAS studies                
used. This was due to certain cohorts AAO being self-reported and other cohorts speciﬁcally recrui ng               
younger onset cases. Nonetheless, the highly signiﬁcant p-value we obtain for the associa on             
mitochondrial genes and AAO of PD (p-value=3.56E-05) and the recognized importance of mitochondrial             
func on in aging would suggest that this ﬁnding is likely to be robust. Furthermore, it is important to                  
recognize that our understanding of mitochondrial biology is far from complete and this is made evident                
by the fact that many individuals with probable gene c forms of mitochondrial disease remain              
undiagnosed.  This in conjunc on with the fact we also removed the mitochondria func on associated              
genes that are known risk hits (such as SNCA) suggests that our analysis likely represents an                
underes mate of the overall contribu on of the mitochondria pathway to sporadic PD. This             
underes mate is illustrated in  Supplementary Figure 1 and 2 , which shows that heritability es mates              
and PRS scores are higher when the PD risk genes are included. But we note that our ul mate goal for                    
this study was to catalog mitochondria speciﬁc gene c risk outside of known risk loci, which we have                 
subsequently reported.  
 
Another possible limita on of this present study is that the sta s cal tools we have used in these                 
analyses are currently limited. For example, MR ul mately relies on the availability of suﬃcient              
quan  es of high quality eQTL data. However, as there is a future focus to; increase data-set sample size,                  
report and characterize phenotypes such as AAO more accurately and con nue to increase the number               
of iden ﬁed mitochondrial disease and func on genes, we will be able to further explore the role of                 
speciﬁc mitochondrial processes in more detail and iden fy their dis nct contribu on to disease             
8 
causa on and progression.  In regard to the MR nominated genes in par cular, further follow-up              
func onal studies will be crucial to validate how these genes contribute to disease risk. Finally it is                 
possible that our focus on one speciﬁc pathway could infer a selec on bias to our analyses. However the                  
fact that our results are consistent across cohorts and the fact that this signiﬁcant associa on is observed                 
in mul ple tests, adds validity to our data. In light of this however a large-scale unbiased approach                 
should be the focus of future pathway related studies to avoid this poten al bias, although this will be                  
diﬃcult given the scope of work and sample size needed.  
 
In summary, in this study we provide robust evidence for the involvement of mitochondrial processes in                
sporadic PD, as opposed to its deﬁned and well established role in the monogenic forms of the disease.                  
In rela on to the 14 novel mitochondrial func on genes that we have iden ﬁed, our data suggests that it                  
is not only mitochondrial quality control and homeostasis which contributes to PD risk but other key                
mitochondrial processes, such as the func on of mitochondrial ribosomes, mirroring the biological            
complexity of mitochondrial disorders. Thus, this study opens the way for the iden ﬁca on of novel               
drug targets in PD causa on and progression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS 
 
Samples and quality control of IPDGC datasets 
 
All genotyping data was obtained from IPDGC datasets, consis ng of 41,321 individuals (18,869 cases 
and 22,452 controls) of European ancestry. Detailed demographic and clinical characteris cs are given in 
Supplementary Table 1 and are explained in further detail in along with detailed quality control (QC) 
methods 6,38 . For sample QC, in short, individuals with low call rate (<95%), discordance between gene c 
and reported sex,  heterozygosity outliers (F sta s c cut-oﬀ of > -0.15 and < 0.15) and ancestry outliers 
9 
(+/- 6 standard devia ons from means of eigenvectors 1 and 2 of the 1000 Genomes phase 3 CEU and 
TSI popula ons from principal components  40 ) were excluded. Further, for genotype QC, variants with a 
missingness rate of > 5%, minor allele frequency < 0.01, exhibi ng Hardy-Weinberg Equilibrium (HWE) < 
1E-5 and palindromic SNPs were excluded. Remaining samples were imputed using the Haplotype 
Reference Consor um (HRC) on the University of Michigan imputa on server under default se ngs with 
Eagle v2.3 phasing based on reference panel HRC r1.1 2016 41,42 . 
 
Curation of genes implicated in mitochondrial disorders and associated with mitochondrial  function 
 
Gene lists were built to encompass diﬀerent levels of evidence for involvement of the respec ve protein 
products in disease phenotypes that relate to mitochondrial func on. The list of genes implicated in 
gene c mitochondrial disorders (“primary ” gene list,  n=196) has the most stringent criteria of evidence 
that the respec ve genes is related to mitochondrial dysfunc on. It consists of 102 nuclear genes listed 
in MITOMAP (downloaded 2015) and 94 sourced from literature review as containing muta ons that 
cause with mitochondrial disease.  
 
The list of genes implicated in mitochondrial func on (“secondary” gene list , n  = 1487) was constructed 
using the OMIM API to iden fy all genes for which the word “mitochondria” (or deriva ves) appeared in 
the free-text descrip on, and by combining this informa on with MitoCarta v2.0 genes with no OMIM 
phenotype. This therefore gathered a list of plausible biological candidate genes, i.e. genes that are 
func onally implicated in mitochondrial func on and morphology for which we may lack gene c 
evidence for mitochondrial disease associa on. 
 
Next, to iden fy novel PD-associated genes, the 349 genes iden ﬁed to be in LD with the PD risk variants 
of interest in the most recent PD meta-analysis (Nalls et al 2018) were removed from both lists  (removed 
genes listed in  Supplementary Table 2 ). The ﬁnal “primary” and “secondary” gene lists are given in 
Supplementary Table 3  and Supplementary Table 4  and  following the removal the PD-associated genes 
were n= 178 and n=1328 respec vely . 
 
 
 
 
 
Cohort-level heritability estimates and meta analysis  
 
G enome-wide complex trait analysis (GCTA) was used to calculate heritability es mates for the four 
largest IPDGC cohorts ( WTCCC PD GWAS (PMID:21044948), Spanish Parkinson's (IPDGC) part2, NIA PD 
GWAS (PMID:19915575), Dutch GWAS (PMID:21248740 ) using non-imputed genotyping data for all 
variants within both mitochondria gene lists using the same workﬂow as  43 . Gene c rela onship matrices 
were calculated for each dataset to iden fy the gene c rela onship between pairs of individuals. 
Gene c rela onship matrices were then input into restricted maximum likelihood analyses to produce 
es mates of the propor on of phenotypic variance explained by the SNPs within each subset of data. 
Principal components (PCs) were generated for each data-set using PLINK (version 1.9). In order to adjust 
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for factors accoun ng to possible popula on substructure, the top twenty generated eigenvectors from 
the PC analysis, age, sex and prevalence were used as basic covariates. Disease prevalence standardized 
for age and gender based on epidemiological reports was speciﬁed at 0.002 43–47 . Summary sta s cs from 
these es mates were produced for all four datasets and were included in the meta-analyses. 
Random-eﬀects meta-analysis using the residual maximum likelihood method, was performed using R 
(version 3.5.1)  package metafor to calculate p-values and generate forest plots 48 .  
 
Risk profiles versus disease status and age at onset 
 
Previous risk proﬁling methods have calculated polygenic risk scores (PRS) using only variants that exhibit 
genome-wide signiﬁcant associated with disease risk. However, in the most recent PD meta analysis, it is 
shown that using variants at thresholds below genome-wide signiﬁcance improves gene c predic ons of 
disease risk ( 6,43 ).  Mirroring this workﬂow, but instead using only variants within gene regions outlined in 
both the primary and secondary gene lists, the R package PRsice2 was used to carry out PRS proﬁling in 
the standard weighted allele dose manner. In addi on, PRsice2 performs permuta on tes ng and 
p-value aware LD pruning to facilitate iden fying the best p-value threshold for variant inclusion to 
construct the PRS. External summary sta s cs u lized in this phase of analysis included data from 
leave-one-out meta-analyses (LOOMAs) that exclude the study in which the PRS was being tested, 
avoiding overﬁ ng/circularity to some degree. LD clumping was implemented under default se ngs 
(window size = 250kb, r 2  > 0.1) and for each dataset 10,000 permuta ons of phenotype-swapping were 
used to generate empirical p-value es mates for each GWAS derived p-value threshold ranging from 
5E-08 to 0.5, at a minimum increment of 5E-08. Each permuta on test in each dataset provided a 
Nagelkerke’s pseudo r 2  a er adjustment for an es mated prevalence of 0.005 and study-speciﬁc PCs 1-5, 
age and sex as covariates. GWAS derived p-value  threshold with the highest pseudo r 2  was selected for 
further analysis. Summary sta s cs were meta-analyzed using random eﬀects (REML) per study-speciﬁc 
dataset using  PRSice2  49 . For the age at onset risk proﬁling, the same workﬂow was followed, however 
instead, age at onset was used as a con nuous variable, as previously reported 38 . To remove possible 
confounders that could possibly drive a false associa on with age we removed  APOE  and  FOXO3 which 
are general markers for aging  50 .  
 
Mendelian randomization to explore possible causal effect of mitochondria function genes  
Both mitochondria gene lists were combined and all genes already associated with PD (i.e. that have 
been iden ﬁed to be in LD with PD risk loci  in the last meta-analysis) were removed, leaving 1432 
unique mitochondria func on gene regions.  
 
We u lized four large-scale  methyla on and expression datasets  through the  summary-data-based 
Mendelian randomiza on (SMR)  ( http://cnsgenomics.com/software/smr ) resource. Summary sta s cs 
were compared to PD outcome summary sta s cs for the mitochondria variants of interest (extracted 
from   4–6,30–34 )  to iden fy possible associa on using the R package TwoSampleMR.  
Tissues were selected based on their relevance to the pathobiology of PD, which ul mately consisted of 
 ssues from 10 brain regions , whole blood, skeletal muscle, and nerve, (a full list of the  ssues u lised 
can be found in  Supplementary Table 5 ). For the methyla on QTLs “middle age” data  was used, which 
was the the oldest available  me point.  For each mitochondria func on variant of interest (considered 
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here the instrumental variable), wald ra os were generated for each variable that tagged a cis-QTL 
(probes within each gene and mee ng a QTL p-value of at least 5E-08 in the original QTL study) and for a 
methyla on or expression probe with a nearby gene. Using the default  SMR protocols, linkage pruning 
and clumping were implemented. Finally for each dataset p-values were adjusted by false discovery rate 
to account for mul ple tes ng. 
 
Co-expression network analysis  
 
Co-expression network analysis was used to determine whether mitochondrial genes associated with PD 
using the SMR analysis are co-expressed with genes associated with monogenic forms of PD in human 
brain. This analysis was performed by using GTEx V6 gene expression data (The GTEx Consor um et al. 
2015; Carithers et al. 2015) to generate co-expression networks for each of the 13 brain  ssues included 
within the GTEx study. The raw FPKM (Fragments Per Kilobase of transcript per Million mapped reads) 
values were corrected for known batch eﬀects, age at death, sex and post-mortem interval, as well as 
unknown eﬀects. The unknown eﬀects were detected with the Surrogate Variable Analysis (SVA) R 
Package (Leek and Storey 2007) and correc on was performed using ComBat (Johnson, Li, and Rabinovic 
2007). The resul ng residuals were used to create a signed network using the 
blockwiseConsensusModules R func on from the WGCNA R package (Langfelder and Horvath 2008) for 
each of the 13  ssues. Next, the modules obtained in each of the 13 networks were assigned to cell 
types using the userListEnrichment R func on implemented in the WGCNA R package, which measures 
enrichment between module-assigned genes and deﬁned brain-related lists using a hypergeometric test. 
The same approach was used to annotate modules with Gene Ontology , REACTOME (Fabregat et al. 
2018) and KEGG (Kanehisa et al. 2016) terms. 
 
Expression-weighted cell-type enrichment (EWCE): evaluating enrichment of mitochondrial genes 
associated with PD risk 
 
Expression-weighted cell-type enrichment (EWCE) ( h ps://github.com/NathanSkene/EWCE ) ( EWCE) was 
used to determine whether mitochondrial genes associated with PD using the MR analysis have higher 
expression within a par cular cell type than expected by chance. The input for the analysis was  1) 
neuronal and glial clusters of the central nervous system (CNS) iden ﬁed in the Linnarsson single-cell 
RNA sequencing dataset (amoun ng to a subset of 114 of the original 265 clusters iden ﬁed) 
( h p://mousebrain.org/ ) and 2) our list of mitochondrial genes highlighted through the MR analysis (see 
Supplementary Table 6 for the full list of Linnarsson CNS neuronal clusters used). 
 
For each gene in the Linnarsson dataset,  cell-type speciﬁcity was es mated (the propor on of a gene’s 
total expression in one cell type compared to all cell types) using the ‘generate.celltype.data’ func on of 
the EWCE package. EWCE with the target list was run with 100,000 bootstrap replicates, which were 
sampled from a background list of genes that excluded all genes without a 1:1 mouse:human ortholog. 
In addi on, transcript length and GC-content biases were controlled for by selec ng bootstrap lists with 
comparable proper es to the target list. The analysis was performed using  major cell-type classes (e.g. 
“telencephalon inhibitory interneurons”, “telencephalon projec ng excitatory neurons”, etc.) and 
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subtypes of these classes (e.g. TEINH6 [“Interneuron-selec ve interneurons, cortex/hippocampus”], 
TEINH7 [“Interneuron-selec ve interneurons, hippocampus”], etc.). Data are displayed as standard 
devia ons from the mean, and any values < 0, which reﬂect a deple on of expression, are displayed as 0. 
P-values were corrected for mul ple tes ng using the Benjamini-Hochberg method over all cell types 
and gene lists displayed.  
 
OMIM data 
Phenotype rela onships and clinical synopses of all OMIM genes were downloaded from 
h p://api.omim.org on the 29th of May 2018. OMIM genes were ﬁltered to exclude provisional, 
non-disease and suscep bility phenotypes retaining 2,898 unique genes that were conﬁdently 
associated to 4,034 Mendelian diseases. The phenotypic informa on rela ng to all genes associated with 
mitochondrial disorders was collated. 
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FIGURE LEGENDS  
 
Figure 1.  Workﬂow of mitochondrial-func on speciﬁc PD analysis  
 
Figure 2.  Forest plots of PRS for Parkinson’s Disease across cohorts.  
Random eﬀect meta analysis results are shown as red diamonds and ﬁxed eﬀects are shown as blue, 
with the centerline of each diamond represen ng the summary PRS for that dataset.  IPDGC NeuroX= 
(Nalls et al 2015, PMID:25444595),  OSLO= Oslo Parkinson's Disease Study, PDBP= Parkinson's Disease 
Biomarker's Program, PPMI= Parkinson's Progression Markers Ini a ve, Baylor = Baylor College of 
Medicine / University of Maryland,  German GWAS= (PMID:19915575), VANCE=Vance (dbGap 
phs000394). 
 
Figure 3.  Forest plots of PRS for the age at onset of Parkinson’s Disease across cohorts.  
Random eﬀect meta analysis results are shown as red diamonds and ﬁxed eﬀects are shown as blue, 
with the centerline of each diamond represen ng the summary PRS for that dataset.  OSLO= Oslo 
Parkinson's Disease Study, PDBP= Parkinson's Disease Biomarker's Program, PPMI= Parkinson's 
Progression Markers Ini a ve,  German GWAS= (PMID:19915575), VANCE=Vance 
 
TABLES 
 
Table 1. Cohort level heritability analysis for the primary and secondary mitochondrial gene lists; 
repor ng es mates for the WTCCC PD GWAS (PMID:21044948), Spanish Parkinson's (IPDGC) part2, NIA 
PD GWAS (PMID:19915575), Dutch GWAS (PMID:21248740) cohorts. Showing heritability es mates 
generated using GCTA and standard error of the es mates (SE).  
 
 Primary Secondary 
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 Heritability es mate  SE of heritabilty es mate Heritability es mate  SE of heritabilty es mate 
WTCCC PD GWAS (PMID:21044948) 0.00321 0.00277 0.00563 0.00688 
Spanish Parkinson's (IPDGC) part2 0.00027 0.00314 0.00629 0.00932 
NIA PD GWAS (PMID:19915575) 0.00945 0.00540 0.03616 0.01365 
Dutch GWAS (PMID:21248740) 0.00000 0.00530 0.03562 0.01681 
 
 
 
Table 2. Summary of random-effects meta-analysis for the primary and secondary mitochondrial gene 
lists .  Here we show the random-eﬀects meta-analysis of  heritability es mates for;  all SNPs in the 
genome  (All SNPs), es mate calculated with for the  SNPs within the primary mitochondria list genes 
(Primary) and the SNPs  within the secondary mitochondria list genes (Secondary).  
 
 
Table 3. Significant functional associations of mitochondrial function genes via two-sample Mendelian 
randomization.  Mul -SNP eQTL Mendelian randomiza on results focusing on the mitochondria 
associated genes (combining the primary and secondary gene lists). Showing the fourteen mitochondria 
func on associated genes that are signiﬁcantly associated with PD risk a er FDR adjustment.  
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Figure 1. 
 
 
Figure 2. 
 
 
 
Figure 3.  
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SUPPLEMENTARY  
 
Table S1. Demographic and clinical characteris cs for all IPDGC genotyping data  
 
Table S2.  Mitochondrial genes iden ﬁed to be in LD with the PD risk variants of interest in the most 
recent PD meta-analysis  that were removed from our list to iden fy novel associa on 
  
Table S3. Primary mitochondria gene list (hg/19) 
 
Table S4. Secondary mitochondria gene list (hg/19) 
 
Table S5 . Tissues and data-sets included in Mendelian Randomisa on analysis  
 
Table S6 . List of the CNS cell clusters used for enrichment-weighted cell-type enrichment (EWCE) and 
results of EWCE analysis for all genes iden ﬁed by two-sample Mendelian randomiza on  
 
Table S7  Coexpression of genes iden ﬁed using two-sample Mendelian randomiza on with genes known 
to cause familial forms of PD 
 
Table S8. Results of co-expression network analysis for all genes iden ﬁed by two-sample Mendelian 
randomiza on  
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Figure S1.  Forest plots of heritability es mates across cohorts for comparison of analysis when  including 
or excluding PD risk genes for the primary and secondary gene lists. Cohort-speciﬁc heritability es mates 
are shown, the size of the square is propor onal to the size of the study. Conﬁdence intervals of the 
summary heritability es mates are shown as red diamonds, with the centerline of each diamond 
represen ng the summary heritability es mate.  
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Figure S2.  Forest plots of PRS across cohorts  for comparison of analysis when including or excluding PD 
risk genes for the primary and secondary gene lists. Random eﬀect meta analysis results are shown as 
red diamonds and ﬁxed eﬀects are shown as blue, with the centerline of each diamond represen ng the 
summary PRS for that dataset. IPDGC NeuroX= (Nallset al 2015, PMID:25444595),  OSLO= Oslo 
Parkinson's Disease Study, PDBP= Parkinson's Disease Biomarker's Program, PPMI= Parkinson's 
Progression Markers Ini a ve, Baylor = Baylor College of Medicine / University of Maryland,  German 
GWAS= (PMID:19915575), VANCE=Vance (dbGapphs000394). 
 
  Figure S3.  Results of enrichment-weighted cell-type enrichment analysis for all genes iden ﬁed by via 
two-sample Mendelian randomiza on  
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